EP1950307A4 - Transfert d'un gène dans des cellules souches épithéliales des voies respiratoires via un vecteur lentiviral pseudotype avec une protéine de spicule de virus arn ou virus adn - Google Patents

Transfert d'un gène dans des cellules souches épithéliales des voies respiratoires via un vecteur lentiviral pseudotype avec une protéine de spicule de virus arn ou virus adn

Info

Publication number
EP1950307A4
EP1950307A4 EP06822478A EP06822478A EP1950307A4 EP 1950307 A4 EP1950307 A4 EP 1950307A4 EP 06822478 A EP06822478 A EP 06822478A EP 06822478 A EP06822478 A EP 06822478A EP 1950307 A4 EP1950307 A4 EP 1950307A4
Authority
EP
European Patent Office
Prior art keywords
virus
spice
gene
protein
transfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06822478A
Other languages
German (de)
English (en)
Other versions
EP1950307B1 (fr
EP1950307A1 (fr
EP1950307B8 (fr
Inventor
Katsuyuki Mitomo
Makoto Inoue
Hitoshi Iwasaki
Mamoru Hasegawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IP PHARMA CO., LTD.
Original Assignee
Dnavec Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnavec Research Inc filed Critical Dnavec Research Inc
Priority to EP15190286.3A priority Critical patent/EP2993235B1/fr
Priority to SI200632015T priority patent/SI1950307T1/sl
Publication of EP1950307A1 publication Critical patent/EP1950307A1/fr
Publication of EP1950307A4 publication Critical patent/EP1950307A4/fr
Publication of EP1950307B1 publication Critical patent/EP1950307B1/fr
Priority to CY20161100081T priority patent/CY1117307T1/el
Application granted granted Critical
Publication of EP1950307B8 publication Critical patent/EP1950307B8/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0688—Cells from the lungs or the respiratory tract
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/609—Vectors comprising as targeting moiety peptide derived from defined protein from viruses positive strand RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP06822478.1A 2005-10-28 2006-10-27 Transfert d'un gène dans des cellules souches épithéliales des voies respiratoires via un vecteur lentiviral pseudotype avec une protéine de spicule de virus arn Active EP1950307B8 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP15190286.3A EP2993235B1 (fr) 2005-10-28 2006-10-27 Transfert génique dans des cellules souches épithéliales des voies aériennes par utilisation d'un vecteur lentiviral similian pseudotypé avec la protéine du spicule d'un virus sendai à arn
SI200632015T SI1950307T1 (sl) 2005-10-28 2006-10-27 Transfer gena v epitelijsko matično celico dihalnih poti z uporabo lentivirusnega vektorja, psevdotipiziranega z RNA virusnim spike proteinom
CY20161100081T CY1117307T1 (el) 2005-10-28 2016-01-28 Μεταφορα γονιδιου εντος επιθηλιακου βλαστοκυτταρου αεροδου με χρηση φακοϊικου φορεα ψευδοτυποποιημενου με πρωτεϊνη αιχμης rna ιου

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005313971 2005-10-28
PCT/JP2006/321517 WO2007049752A1 (fr) 2005-10-28 2006-10-27 Transfert d’un gene dans des cellules souches epitheliales des voies respiratoires via un vecteur lentiviral pseudotype avec une proteine de spicule de virus arn ou virus adn

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP15190286.3A Division-Into EP2993235B1 (fr) 2005-10-28 2006-10-27 Transfert génique dans des cellules souches épithéliales des voies aériennes par utilisation d'un vecteur lentiviral similian pseudotypé avec la protéine du spicule d'un virus sendai à arn
EP15190286.3A Division EP2993235B1 (fr) 2005-10-28 2006-10-27 Transfert génique dans des cellules souches épithéliales des voies aériennes par utilisation d'un vecteur lentiviral similian pseudotypé avec la protéine du spicule d'un virus sendai à arn

Publications (4)

Publication Number Publication Date
EP1950307A1 EP1950307A1 (fr) 2008-07-30
EP1950307A4 true EP1950307A4 (fr) 2010-09-08
EP1950307B1 EP1950307B1 (fr) 2015-12-23
EP1950307B8 EP1950307B8 (fr) 2016-02-24

Family

ID=37967860

Family Applications (2)

Application Number Title Priority Date Filing Date
EP06822478.1A Active EP1950307B8 (fr) 2005-10-28 2006-10-27 Transfert d'un gène dans des cellules souches épithéliales des voies respiratoires via un vecteur lentiviral pseudotype avec une protéine de spicule de virus arn
EP15190286.3A Active EP2993235B1 (fr) 2005-10-28 2006-10-27 Transfert génique dans des cellules souches épithéliales des voies aériennes par utilisation d'un vecteur lentiviral similian pseudotypé avec la protéine du spicule d'un virus sendai à arn

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP15190286.3A Active EP2993235B1 (fr) 2005-10-28 2006-10-27 Transfert génique dans des cellules souches épithéliales des voies aériennes par utilisation d'un vecteur lentiviral similian pseudotypé avec la protéine du spicule d'un virus sendai à arn

Country Status (13)

Country Link
US (4) US20090162320A1 (fr)
EP (2) EP1950307B8 (fr)
JP (3) JPWO2007049752A1 (fr)
KR (1) KR20080068098A (fr)
CN (1) CN101351557A (fr)
CA (1) CA2627485C (fr)
CY (1) CY1117307T1 (fr)
DK (1) DK1950307T3 (fr)
ES (2) ES2726176T3 (fr)
HU (1) HUE028512T2 (fr)
PT (1) PT1950307E (fr)
SI (1) SI1950307T1 (fr)
WO (1) WO2007049752A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2526339A (en) * 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
KR101753069B1 (ko) 2015-07-17 2017-07-04 서울대학교병원 헤마글루티닌-뉴라미니다아제와 f 단백질을 과발현하는 중간엽줄기세포 및 그 용도
IL273923B2 (en) * 2017-10-20 2024-08-01 Genethon Using syncytin for drug targeting and gene delivery to lung tissue
CN111378785A (zh) * 2020-03-12 2020-07-07 仁宽(上海)生物科技有限公司 用于核酸诊断新型冠状病毒2019-nCov的假病毒标准品及其应用
CN111088408A (zh) * 2020-03-20 2020-05-01 广州凯普医药科技有限公司 一种新冠病毒、甲乙流感及呼吸道合胞病毒检测试剂盒
CN112011521A (zh) * 2020-06-15 2020-12-01 浙江迪福润丝生物科技有限公司 一种重组新城疫病毒载体新型冠状病毒疫苗候选株及其构建方法和应用
CA3185952A1 (fr) * 2020-07-15 2022-01-20 Pierre Charneau Compositions immunogenes contre le sars-cov-2, vaccins et procedes
WO2022055894A1 (fr) * 2020-09-08 2022-03-17 The Regents Of The University Of California Glycoprotéine de spicule sars-cov-2 pour la génération et le pseudotypage de virus
CN119137279A (zh) * 2022-04-11 2024-12-13 Ip2Ipo创新有限公司 组合治疗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032898A2 (fr) * 1999-11-02 2001-05-10 Dnavec Research Inc. Vecteur du virus de sendai recombine servant a introduire des genes exogenes dans l'epithelium des voies respiratoires

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162215A (en) * 1988-09-22 1992-11-10 Amgen Inc. Method of gene transfer into chickens and other avian species
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5576201A (en) * 1994-01-14 1996-11-19 Alexion Pharmaceuticals, Inc. Retroviral vector particles for transducing non-proliferating cells
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
DK0864645T3 (da) * 1995-10-31 2005-10-24 Dnavec Research Inc Negativstrenget RNA-virusvektor med autonom replikeringsaktivitet
DK0863202T3 (da) 1995-11-01 2010-09-27 Dnavec Research Inc Rekombinant Sendai-virus
WO1997016171A1 (fr) 1995-11-01 1997-05-09 Dnavec Research Inc. Liposome a membrane fusible faisant appel a un virus sendai recombinant
WO1998027217A1 (fr) 1996-12-16 1998-06-25 Eisai Co., Ltd. Procede pour preparer un vecteur de retrovirus pour la therapie genique
WO1999013905A1 (fr) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Mutants de poche de fixation de recepteur d'hemagglutinine de virus de grippe a
US6749863B1 (en) * 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
US5962274A (en) * 1998-03-13 1999-10-05 Wake Forest University Viral vector directed to predetermined target cells
US6828138B1 (en) * 1998-08-11 2004-12-07 Dnavec Research Inc. Recombinant sendai virus vector including a gene encoding a chemokine
DE19851282A1 (de) 1998-11-06 2000-05-11 Schweiz Serum & Impfinst Zusammensetzung einer pharmazeutisch wirksamen Substanz, appliziert in einem spezifischen Delivery-System zur Prävention und Behandlung von Infektions-Krankheiten
DE19909769A1 (de) * 1999-03-05 2000-09-07 Bundesrepublik Deutschland Let Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen
DE60039292D1 (de) 1999-05-18 2008-08-07 Dnavec Research Inc Ribonukleoproteinkomplex aus paramyxovirus
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
US20020169306A1 (en) * 1999-05-18 2002-11-14 Kaio Kitazato Envelope gene-deficient paramyxovirus vector
ES2288473T3 (es) 1999-05-18 2008-01-16 Dnavec Research Inc. Vector de virus deficiente en el gen de la envoltura de paramyxoviridae.
CN1367839A (zh) * 1999-09-06 2002-09-04 株式会社载体研究所 含有已改变的转录起始序列的副粘病毒
US7314614B1 (en) * 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
KR100774796B1 (ko) * 2000-01-19 2007-11-07 가부시키가이샤 디나벡크 겐큐쇼 파라믹소바이러스 벡터의 혈관으로의 유전자 도입용도
CN1248740C (zh) * 2000-03-30 2006-04-05 株式会社载体研究所 使用仙台病毒载体的aids病毒疫苗
CA2322057A1 (fr) * 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus utilises comme vecteurs pour le transfert de genes etrangers
KR100807016B1 (ko) * 2000-06-01 2008-02-25 가부시키가이샤 디나벡크 겐큐쇼 헤마글루티닌 활성을 갖는 막단백질을 포함하는 슈도타입레트로바이러스 벡터
JP5014535B2 (ja) 2000-06-15 2012-08-29 田辺三菱製薬株式会社 カニクイザル由来胚性幹細胞
EP1297852A4 (fr) * 2000-06-27 2004-12-29 Dnavec Research Inc Vecteur de virus pour introduction de gene dans des cellules renales
WO2002031138A1 (fr) * 2000-10-06 2002-04-18 Dnavec Research Inc. Vecteur de paramyxovirus permettant de transferer un gene etranger dans le muscle squelettique
JP2002142770A (ja) 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
DE60133767T2 (de) * 2000-11-27 2009-06-25 Dnavec Research Inc., Tsukuba Für fibroblasten-wachstumsfaktor 2 (fgf2) kodierender paramyxovirus-vektor und dessen verwendung
WO2002101057A1 (fr) 2001-06-08 2002-12-19 Dnavec Research Inc. Transfert genique dans des cellules souches embryonnaires de primate a l'aide d'un virus de l'immunodeficience simienne de pseudo type vsv-g utilise comme vecteur
GB0202569D0 (en) 2002-02-04 2002-03-20 Oxford Biomedica Ltd Delivery means
JPWO2003092738A1 (ja) * 2002-04-30 2005-09-08 株式会社ディナベック研究所 ヘマグルチニン活性を低下させた薬剤または遺伝子運搬組成物
US20050255123A1 (en) * 2002-04-30 2005-11-17 The Trustees Of The University Of Pennsylvania Chimeric ebola virus envelopes and uses therefor
AU2003234775A1 (en) 2002-04-30 2003-11-17 Dnavec Research Inc. Vector with modified protease-dependent tropism
US20050191617A1 (en) 2002-06-03 2005-09-01 Makoto Inoue Pramyxovirusl vectors encoding antibody and utilization thereof
AU2003261931A1 (en) 2002-09-04 2004-03-29 Dnavec Research Inc. Process for producing virus vector containing membrane protein having sialic acid-binding activitiy in envelope with the use of gram-positive bacterium-origin neuraminidase
EP1561819A4 (fr) 2002-10-24 2006-03-22 Dnavec Research Inc Procede permettant de transferer des genes dans des lymphocytes t
US20050113298A1 (en) * 2003-09-15 2005-05-26 The Brigham And Women's Hospital, Inc. Receptor binding peptides derived from the SARS S protein
WO2005038035A2 (fr) * 2003-10-15 2005-04-28 University Of Iowa Research Foundation Procedes de production et d'utilisation de retrovirus pseudotypes in vivo
WO2005087936A1 (fr) 2004-03-16 2005-09-22 Dnavec Research Inc. Procédé de transfert de gène dans une cellule embryonaire souche

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032898A2 (fr) * 1999-11-02 2001-05-10 Dnavec Research Inc. Vecteur du virus de sendai recombine servant a introduire des genes exogenes dans l'epithelium des voies respiratoires

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ASANO T ET AL: "Highly efficient gene transfer into primate embryonic stem cell with a simian lentivirus vector", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US LNKD- DOI:10.1006/MTHE.2002.0655, vol. 6, no. 2, 1 August 2002 (2002-08-01), pages 162 - 167, XP002956700, ISSN: 1525-0016 *
COPRENI E ET AL: "Lentivirus-mediated gene transfer to the respiratory epithelium: a promising approach to gene therapy of cystic fibrosis.", GENE THERAPY OCT 2004 LNKD- PUBMED:15454960, vol. 11 Suppl 1, October 2004 (2004-10-01), pages S67 - S75, XP002593654, ISSN: 0969-7128 *
KLINK D ET AL: "Gene delivery systems-gene therapy vectors for cystic fibrosis", JOURNAL OF CYSTIC FIBROSIS, ELSEVIER LNKD- DOI:10.1016/J.JCF.2004.05.042, vol. 3, 1 August 2004 (2004-08-01), pages 203 - 212, XP004556460, ISSN: 1569-1993 *
KOBINGER G P ET AL: "Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo.", NATURE BIOTECHNOLOGY MAR 2001 LNKD- PUBMED:11231554, vol. 19, no. 3, March 2001 (2001-03-01), pages 225 - 230, XP002593652, ISSN: 1087-0156 *
MITOMO ET AL: "355. Towards Cystic Fibrosis and Airway Gene Therapy: Evaluation of EGFP Gene Expression in Murine Nasal Airways Mediated by Simian Immunodeficiency Virus Vectors Pseudotyped with Sendai Virus Glycoproteins F and HN", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 11, 15 August 2005 (2005-08-15), pages 139, XP005015694, ISSN: 1525-0016 *
SCHNELL T ET AL: "DEVELOPMENT OF A SELF-INACTIVATING, MINIMAL LENTIVIRUS VECTOR BASEDON SIMIAN IMMUNODEFICIENCY VIRUS", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US LNKD- DOI:10.1089/10430340050015905, vol. 11, 1 January 2000 (2000-01-01), pages 439 - 447, XP000916370, ISSN: 1043-0342 *
See also references of WO2007049752A1 *
SINN PATRICK L ET AL: "Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer", JOURNAL OF VIROLOGY, vol. 79, no. 20, 1 October 2005 (2005-10-01), pages 12818 - 12827, XP002593653, ISSN: 0022-538X *
YONEMITSU Y ET AL: "Efficient gene transfer to airway epithelium using recombinant Sendai virus", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US LNKD- DOI:10.1038/79463, vol. 18, no. 9, 1 September 2000 (2000-09-01), pages 970 - 973, XP002165781, ISSN: 1087-0156 *

Also Published As

Publication number Publication date
EP1950307B1 (fr) 2015-12-23
SI1950307T1 (sl) 2016-02-29
CA2627485C (fr) 2017-02-21
JP2013055941A (ja) 2013-03-28
DK1950307T3 (en) 2016-02-15
WO2007049752A1 (fr) 2007-05-03
US20160281109A1 (en) 2016-09-29
CN101351557A (zh) 2009-01-21
US20190225986A1 (en) 2019-07-25
US10017784B2 (en) 2018-07-10
ES2726176T3 (es) 2019-10-02
CY1117307T1 (el) 2017-04-26
US20150174198A1 (en) 2015-06-25
EP1950307A1 (fr) 2008-07-30
JP2015126753A (ja) 2015-07-09
JP5776662B2 (ja) 2015-09-09
PT1950307E (pt) 2016-02-29
KR20080068098A (ko) 2008-07-22
HUE028512T2 (en) 2016-12-28
ES2561060T3 (es) 2016-02-24
EP2993235B1 (fr) 2019-02-13
US20090162320A1 (en) 2009-06-25
EP1950307B8 (fr) 2016-02-24
EP2993235A1 (fr) 2016-03-09
CA2627485A1 (fr) 2007-05-03
JPWO2007049752A1 (ja) 2009-04-30

Similar Documents

Publication Publication Date Title
Dolan et al. Mechanisms and concepts in RNA virus population dynamics and evolution
Tatham et al. The S-poor prolamins of wheat, barley and rye: Revisited
UA102503C2 (en) Interleukin-13 binding proteins
EP2393933A4 (fr) Enzymes de copie de l'arn et de l'adn
EP2350670A4 (fr) Biocapteur à connecteur de protéine motrice d'encapsulation d'adn viral à intégration membranaire pour séquençage d'adn et autres utilisations
ATE398672T1 (de) Immortalisierte vogelzellinien zur virusproduktion
EP2046962A4 (fr) Adn codant pour une protéine en doigts de zinc à domaine ring et utilisation de l'adn dans des vecteurs et des bactéries et dans des plantes
IS8282A (is) Kortlagning genamengja starfrænna DNA þátta og frumuprótína
EP1950307A4 (fr) Transfert d'un gène dans des cellules souches épithéliales des voies respiratoires via un vecteur lentiviral pseudotype avec une protéine de spicule de virus arn ou virus adn
EA202090661A1 (ru) Мутантные гены протопорфириноген ix оксидазы (ppx)
WO2007133682A3 (fr) Procédés de détection à 100 % de l'identité d'une séquence pour divers génomes
BRPI0509497A (pt) seqüência de polipeptìdeos na modulação do efeito imunosupressor de proteìnas virais
WO2006134154A3 (fr) Haplotype de gene enpp1 (pc-1) associe au risque de developper une obesite et un diabete de type 2 et applications correspondantes
WO2006120230A3 (fr) Molecules de liaison specifiques de cellule hote capables de neutraliser des virus et leurs utilisations
WO2009082085A3 (fr) Molécules d'acide nucléique hautement infectieuses provenant du virus de la marbrure du poivron et vecteur viral végétal issu de celles-ci
EP2061316A4 (fr) Nucleosides d'azole et utilisation en tant qu'inhibiteurs de polymerases d'arn et d'adn viral
Pérez-León et al. Identification of the agent causing anthracnose on Sansevieria spp., in Costa Rica
EP2173873A4 (fr) Protéine et séquence d'adn codant pour une activité de type subtilisine adaptée au froid
EP2239325A4 (fr) Virus se développant dans des cellules hypoxiques ou vecteur viral exprimant un gène dans celles-ci
JP2005528912A5 (fr)
WO2006071884A3 (fr) Agents therapeutiques a base d'oligonucleotides
Olguin-Nava et al. Building blocks of understanding: Constructing a reverse genetics platform for studying determinants of SARS-CoV-2 replication
WO2007101103A3 (fr) Compositions et analyses pour l'inhibition d'une infection hcv
WO2007019532A3 (fr) Aptamères peptidiques se liant aux protéines rep de virus ssdna
EP1975238A4 (fr) Construction génique, vecteur et vaccin d'adn pour la vaccination d'animaux aquatiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080528

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20100810

17Q First examination report despatched

Effective date: 20110715

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DNAVEC CORPORATION

RIN1 Information on inventor provided before grant (corrected)

Inventor name: INOUE, MAKOTO C/O DNAVEC CORPORATION

Inventor name: GRIESENBACH, UTA

Inventor name: MITOMO, KATSUYUKI C/O DNAVEC CORPORATION

Inventor name: HASEGAWA, MAMORU C/O DNAVEC CORPORATION

Inventor name: ALTON, ERIC W

Inventor name: IWASAKI, HITOSHI C/O DNAVEC CORPORATION

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/867 20060101AFI20150115BHEP

Ipc: C12N 5/10 20060101ALI20150115BHEP

Ipc: A61K 35/76 20150101ALI20150115BHEP

Ipc: A61K 48/00 20060101ALI20150115BHEP

Ipc: A61K 38/17 20060101ALI20150115BHEP

Ipc: A61P 11/00 20060101ALI20150115BHEP

Ipc: C07K 14/47 20060101ALI20150115BHEP

Ipc: C12N 15/86 20060101ALI20150115BHEP

Ipc: A61K 38/00 20060101ALI20150115BHEP

Ipc: C12N 5/071 20100101ALI20150115BHEP

INTG Intention to grant announced

Effective date: 20150205

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150625

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RIN1 Information on inventor provided before grant (corrected)

Inventor name: INOUE, MAKOTO C/O DNAVEC CORPORATION

Inventor name: IWASAKI, HITOSHI C/O DNAVEC CORPORATION

Inventor name: ALTON, ERIC W

Inventor name: GRIESENBACH, UTA

Inventor name: MITOMO, KATSUYUKI C/O ID PHARMA CO., LTD

Inventor name: HASEGAWA, MAMORU C/O ID PHARMA CO., LTD

INTG Intention to grant announced

Effective date: 20151103

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IP PHARMA CO., LTD.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: SERVOPATENT GMBH, CH

Ref country code: CH

Ref legal event code: EP

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNG INHABER

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 766589

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160115

RIN2 Information on inventor provided after grant (corrected)

Inventor name: ALTON, ERIC W

Inventor name: INOUE, MAKOTO C/O ID PHARMA CO., LTD.

Inventor name: HASEGAWA, MAMORU C/O ID PHARMA CO., LTD

Inventor name: MITOMO, KATSUYUKI C/O ID PHARMA CO., LTD

Inventor name: GRIESENBACH, UTA

Inventor name: IWASAKI, HITOSHI C/O ID PHARMA CO., LTD.

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006047566

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20160211

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2561060

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20160224

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20160122

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: AT

Ref legal event code: HC

Ref document number: 766589

Country of ref document: AT

Kind code of ref document: T

Owner name: ID PHARMA CO., LTD., JP

Effective date: 20160212

REG Reference to a national code

Ref country code: SE

Ref legal event code: RPOT

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151223

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151223

REG Reference to a national code

Ref country code: DE

Ref legal event code: R083

Ref document number: 602006047566

Country of ref document: DE

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20160400140

Country of ref document: GR

Effective date: 20160414

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 20738

Country of ref document: SK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151223

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160423

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151223

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151223

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006047566

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20160926

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E028512

Country of ref document: HU

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 20738

Country of ref document: SK

Effective date: 20161027

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161027

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161028

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161027

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161028

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161028

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20170727

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170727

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 766589

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161027

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161027

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 766589

Country of ref document: AT

Kind code of ref document: T

Effective date: 20151223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151223

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151223

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: WANNERSTRASSE 9/1, 8045 ZUERICH (CH)

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230515

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251101

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20251021

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20251021

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20251022

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20251027

Year of fee payment: 20

Ref country code: IT

Payment date: 20251024

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20251029

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20251021

Year of fee payment: 20

Ref country code: GR

Payment date: 20251022

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20251101

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20251024

Year of fee payment: 20

Ref country code: CZ

Payment date: 20251021

Year of fee payment: 20

Ref country code: CY

Payment date: 20250923

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20251210

Year of fee payment: 20